225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome Interventions: Biological: Actinium Ac 225-DOTA-Daratumumab; Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration; Procedure: Bone Marrow Biopsy; Procedure: Computed Tomography; Biological: Daratumumab; Procedure: Echocardiography; Drug: Fludarabine; Procedure: Hematopoietic Cell Transplantation; Biological: Indium In 111-DOTA-Daratumumab; Drug: Melphalan; Procedure: Multigated Acquisition Scan; Procedure: Radionuclide Imaging; Procedure: Single Photon Emission Computed Tomography; Drug: Sirolimus; Drug: Tacrolimus; Radiation: Total Marrow and Lymphoid Irradiation Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Bone Marrow Aspiration and Biopsy | Cancer | Cancer & Oncology | CT Scan | Leukemia | Mergers and Aquisitions | Myelodysplastic Syndrome | PET Scan | Prograf | Research | SPECT | Stem Cell Therapy | Stem Cells | Tacrolimus | Transplants